Cardlytics Inc. (NASDAQ: CDLX) closed the day trading at $3.63 down -2.94% from the previous closing price of $3.74. In other words, the price has decreased by -$0.1100 from its previous closing price. On the day, 691295 shares were traded. CDLX stock price reached its highest trading level at $4.0400 during the session, while it also had its lowest trading level at $3.5050.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
For a better understanding of CDLX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.00. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 1.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on September 08, 2022, Downgraded its rating to Underweight and sets its target price to $13 from $14 previously.
On July 14, 2022, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $72 to $15.
BofA Securities Downgraded its Neutral to Underperform on July 13, 2022, while the target price for the stock was maintained at $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 09 when BALEN JOHN V bought 3,000 shares for $3.80 per share. The transaction valued at 11,398 led to the insider holds 61,798 shares of the business.
BALEN JOHN V bought 6,000 shares of CDLX for $23,698 on Nov 08. The Director now owns 58,798 shares after completing the transaction at $3.95 per share. On Nov 08, another insider, Grimes Scott D., who serves as the Director of the company, sold 494 shares for $3.98 each. As a result, the insider received 1,969 and left with 248,785 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.45 while its Price-to-Book (P/B) ratio in mrq is 0.57.
Stock Price History:
Over the past 52 weeks, CDLX has reached a high of $62.90, while it has fallen to a 52-week low of $3.50. The 50-Day Moving Average of the stock is 5.8075, while the 200-Day Moving Average is calculated to be 11.0115.
Shares Statistics:
Over the past 3-months, CDLX traded about 687.23K shares per day on average, while over the past 10 days, CDLX traded about 788.75k shares per day. A total of 33.31M shares are outstanding, with a floating share count of 32.24M. Insiders hold about 2.10% of the company’s shares, while institutions hold 95.80% stake in the company. Shares short for CDLX as of Jan 12, 2023 were 3.97M with a Short Ratio of 3.36M, compared to 4.29M on Dec 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 11.98% and a Short% of Float of 17.09%.
Earnings Estimates
Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of -$0.46 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.59, while EPS last year was -$0.15. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.15 and low estimates of -$0.7.
Analysts are recommending an EPS of between -$1.71 and -$1.9 for the fiscal current year, implying an average EPS of -$1.8. EPS for the following year is -$1.65, with 4 analysts recommending between -$1.27 and -$2.42.
Revenue Estimates
6 analysts predict $83.54M in revenue for the current quarter. It ranges from a high estimate of $87.4M to a low estimate of $78.68M. As of the current estimate, Cardlytics Inc.’s year-ago sales were $90.05M, an estimated decrease of -7.20% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $68.26M, an increase of 0.50% over than the figure of -$7.20% in the same quarter last year. There is a high estimate of $73.5M for the next quarter, whereas the lowest estimate is $59.23M.
A total of 6 analysts have provided revenue estimates for CDLX’s current fiscal year. The highest revenue estimate was $303.4M, while the lowest revenue estimate was $294.71M, resulting in an average revenue estimate of $299.58M. In the same quarter a year ago, actual revenue was $267.12M, up 12.20% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $318.17M in the next fiscal year. The high estimate is $340.7M and the low estimate is $287.93M. The average revenue growth estimate for next year is up 6.20% from the average revenue estimate for this year.
